1892-P: Acceptability of Automated Insulin Delivery in the Hospital
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1892-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JENNA M. FEELEY und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Inpatient diabetes management with multiple daily injections is often suboptimal. Automated insulin delivery (AID) can improve glycemic control by dynamically adjusting insulin doses using glucose trend-predictive algorithms. We evaluated the acceptability of AID and continuous glucose monitoring (CGM) in the hospital setting among nurses and people with diabetes (PwD) naïve to AID.
Methods
Surveys (PwD n=73; nurses n=89) and in-depth interviews (PwD n=24; nurses n=15) were conducted as part of the AIDING randomized controlled trial (NCT05590143). Measures assessed attitudes toward AID, including perceived burden, ethicality, effectiveness, intervention coherence, opportunity costs, and self-efficacy, aligned with the Theoretical Framework of Acceptability (TFA).
Results
People with diabetes (mean age 55 years; 36% female; 58% Black, 37% White) and nurses reported high acceptability of AID and CGM (Table). PwD valued fewer fingersticks and automated insulin adjustments. Nurses perceived improved glycemic control with AID, while reporting mixed impressions of inpatient practicality and identifying perceived “noncompliance” as a consideration in patient selection.
Conclusion
Both PwD and nurses reported positive experiences with diabetes technology, with high acceptability and perceived glycemic benefits of AID. Stigma warrants further study as a barrier to implementation. Disclosure J.M. Feeley: Research Support; Current; Dexcom, Inc. M.S. Hughes: Consultant; Current; Dexcom, Inc., Sanofi, Sequel Med Tech, LLC. S. Usman: None. R. Parab: None. N. Gonzalez: None. L. Chadalawada: None. S. Argeseanu Cunningham: None. E. Faulds: Research Support; Current; Dexcom, Inc. Research Support; Ended; Insulet Corporation. Other - Speaker; Ended; Medscape. G. Davis: Research Support; Current; Insulet Corporation, Sequel Med Tech. R. Lal: Consultant; Current; Abbott Diabetes, Adaptyx Biosciences. Consultant; Ended; Biolinq, Capillary Biomedical, Deep Valley Labs. Consultant; Current; Gluroo, Portal Diabetes, Tidepool. Advisory Panel; Ended; ProventionBio, Lilly, Sanofi, Rezolute. S. Brown: Research Support; Current; Insulet Corporation, Tandem Diabetes Care, Inc., Dexcom, Inc. Research Support; Ended; Roche Diabetes Care, Tolerion, Inc. F.J. Pasquel: Research Support; Current; Dexcom, Inc., Insulet Corporation, Ideal Medical Technologies. Research Support; Ended; Novo Nordisk, Tandem Diabetes Care, Inc. Consultant; Ended; Insulet Corporation. M. Weber: None. Funding The National Institute of Diabetes and Digestive and Kidney Diseases (R01DK138366), with device support from Insulet and Dexcom, Inc.
Zitieren
APA
FEELEY, J. M., HUGHES, M. S., USMAN, S., PARAB, R., GONZALEZ, N., CHADALAWADA, L., CUNNINGHAM, S. A., FAULDS, E., DAVIS, G., LAL, R., BROWN, S., PASQUEL, F. J., & WEBER, M. B. (2026). 1892-P: Acceptability of Automated Insulin Delivery in the Hospital. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1892-p
Vancouver
FEELEY JM, HUGHES MS, USMAN S, PARAB R, GONZALEZ N, CHADALAWADA L, et al. 1892-P: Acceptability of Automated Insulin Delivery in the Hospital. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1892-p
BibTeX
@article{FEELEY2026,
author = {FEELEY, JENNA M. and HUGHES, MICHAEL S. and USMAN, SABEENA and PARAB, ROHIT and GONZALEZ, NICOLAS and CHADALAWADA, LAYA and CUNNINGHAM, SOLVEIG ARGESEANU and FAULDS, EILEEN and DAVIS, GEORGIA and LAL, RAYHAN and BROWN, SUE and PASQUEL, FRANCISCO J. and WEBER, MARY BETH},
title = {1892-P: Acceptability of Automated Insulin Delivery in the Hospital},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1892-p}
}
EUVIMED